期刊文献+

腹膜透析患者的脂质变化 被引量:3

The changes of serum lipid level in patients underwent peritoneal dialysis
原文传递
导出
摘要 目的探讨连续性非卧床腹膜透析(CAPD)患者的脂质变化。方法测定84例CAPD患者血脂水平,比较其透析前后脂质改变的差异,并与80例健康人作对照。结果 CAPD患者维持透析治疗1年以后,血清总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、载脂蛋白B(ApoB)、脂蛋白a(LPa)增高,高密度脂蛋白胆固醇(HDL-C)、载脂蛋白A(ApoA)降低。结论慢性肾衰患者存在脂代谢异常,腹膜透析方式不能纠正脂代谢异常。 Objective To investigate the changes of serum lipid level in the patients underwent continuous ambulatory peritoneal dialysis(CAPD).Methods Serum lipid levels were determined in 84 patients underwent CAPD(group A) and 80 healthy people(group C).Results Compared to before,serum total cholesterol(TC),triglyceride(TG),low-density lipoprotein(LDL)-C,apolipoprotein(Apo)B and lipoprotein a(LPa) were obviously increased,while high-density lipoprotein(HDL)-C and ApoA were obviously decreased one year after CAPD.Conclusion The lipid metabolism is abnormal in the patients with chronic renal failure,which can not be corrected by peritoneal dialysis.
出处 《江苏医药》 CAS CSCD 北大核心 2011年第10期1181-1183,共3页 Jiangsu Medical Journal
关键词 腹膜透析 脂质代谢 Peritoneal dialysis Lipid metabolism
  • 相关文献

参考文献8

  • 1Wanner C, Drechsler C, Krane V. Lipid metabolism in chronic kidney disease: the role of stains in cardiovascular risk[J]. J Ren Nutr, 2007,17(1) : 75-78.
  • 2Muntner P,Coresh J,Smith JC,et al. Plasma lipids and risk of developingrenal dysfunction: the atherosclerosis risk in communities study[J]. Kidney Int, 2000,58 (1) : 293-301.
  • 3Johansson AC, Samuelsson O, Attman PO, et al. Dyslipidemia in peritoneatdialysis relation to dialytic variables[J]. Peit Dial Int, 2000,20(3) : 306-314.
  • 4Bredie SJ, Bosch FH, Demacker PN, et al. Effects of peritoneal dialysiswith an overnight icodextrin dwell on parameters of glucose and lipidmetabolism [J]. Perit Dial Int, 2001,21 ( 3 ) :275-281.
  • 5张晓洁,刘惠兰.左旋肉毒碱(可益能)在血液透析患者中的临床应用研究[J].中国血液净化,2002,1(10):18-21. 被引量:28
  • 6Wheeler DC. Abnorma lit ies of lipopr otein met aboli sm in CAPD patients[J]. Kidney Int, 1996,56 (Suppl 1) : 41-46.
  • 7Navaneethan SD, Pansini F, Perkovic V, et al. HMG CoA reduetase inhibitors (statins) for people with chornic kidney disease not requiring dialysis[J]. Cochrane Database Syst Rev, 2009,15 (3) :CD007784.
  • 8Navaneethan SD, Nigwekar SU, Perkovie V, et al. HMG CoA reduetase inhibitors (statins) for dialysis patients[J]. Cochrane Database Syst Rev, 2009,8(3) : CD004289.

二级参考文献7

  • 1[1]Borum PR. Plasma carnitine compartment and red blood cell carnitine compartment of healthy adults. Am J Clin Nutr, 1987,46:437-441
  • 2[2]Borum PR. Changing perspective of carnitine function and the need for exogenous carnitine of patients treated with hemodialysis. Am J Clin Nutr,1996,976-977
  • 3[3]Giovenali P, Fanocchio D, Montanari G, et al. Selective trophic effect of L-carnitine in type I and type II skeletal muscle fibers. Kidney Int,1994,46:1616-1619
  • 4[4]Gloggler A, Bulla M, Furst P. Effect of low dose supplementation of L-carnitine on lipid metabolism in hemodialysis children. Kidney Int,1989,36 (supple27): S256-S258
  • 5[5]Golper TA, Wolfson M,Ahmod S,et al. Multicenter trial of L-carnitine in maintenance hemodialysis patients. I.Carnitine concentrations and lipid effects. Kidney Int, 1990,38:904-911
  • 6[6]Kooistra MP, Sreugernberg A, Van ESA. The response to recombinant human erythropoietin in patients with the anemia of end-stage renal disease is correlated with serum carnitine levels. Nephron, 1991,57:127-128
  • 7[7]Boran M, Dalva I, Gonenc F,et al. Response to recombinant human erythropoietin(r-HuEPO) and L-carnitine combination in patients with anemia of end-stage renal disease. Nephron,1996,73:314-315

共引文献27

同被引文献33

引证文献3

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部